Drug Research
Fusion Antibodies and Queens University Belfast Receive Invest Northern Ireland Grant to Boost Research and Development for COVID-19 Antibodies
Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts. Within...
Clinical Trials
Covid-19: Russia’s Sputnik V vaccine confirms 91.4% efficacy
Russia’s Sputnik V vaccine has demonstrated an efficacy of over 90 percent, according to the Gamaleya Center and the Russian Direct Investment Fund.
“Evaluation of efficacy was carried out among volunteers 21 days after receiving the first dose of the...
News
Biogen Files New Drug Application for Aducanumab in Japan
Biogen and Eisai, Co., Ltd. announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer’s disease. Aducanumab, an amyloid beta-targeting antibody, has...
News
U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the U.S. government has exercised its option to purchase an additional 100 million doses of...
News
AstraZeneca reports Trixeo Aerosphere approved in EU for COPD maintenance
AstraZeneca’s Trixeo Aerosphere has been approved in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS)...
News
SpiceXpress strengthens pharma cold chain capabilities with Om partnership
SpiceXpress, the cargo division of India-based carrier SpiceJet, has partnered with Om Logistics to strengthen its capabilities to transport temperature-sensitive Covid-19 vaccines.
The carrier said the partnership aims to provide a “speedy, seamless and reliable solution” for the movement of...
Clinical Trials
Sanofi, GSK COVID-19 vaccine rollout delayed on low immune response in older adults
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read